LBPMedicine(SH:688393) Xin Lang Cai Jing·2026-01-23 03:17Group 1 - The core point of the news is that Anbiping's stock price increased by 5.34% to 30.40 CNY per share, with a total market capitalization of 2.844 billion CNY as of the report date [1] - Anbiping, established on July 6, 2005, specializes in the research, production, and sales of in vitro diagnostic reagents and instruments, with 79.72% of its revenue coming from self-produced products [1] - The company's revenue composition includes 13.11% from purchased products, 5.90% from service income, and 1.27% from other sources [1] Group 2 - Longcheng Fund's Longcheng Consumption Value Mixed A (200006) is among the top ten circulating shareholders of Anbiping, holding 850,000 shares, which represents 0.91% of the circulating shares [2] - The fund has achieved a year-to-date return of 14.68% and a one-year return of 34.59%, ranking 477 out of 8,847 and 3,667 out of 8,099 in its category, respectively [2] - Longcheng Consumption Value Mixed A has a total asset size of 474 million CNY and has generated a cumulative return of 291.29% since its inception on April 6, 2006 [2]